Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283075 · ClinicalTrials.gov registry record · Phase 1
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
A Phase 1 study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00283075 is a Phase 1 study that has completed, run by The Rogosin Institute. The registered enrollment target is 56 participants.
The verdict
NCT00283075, a Phase 1 study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tested in tumor models in mice and rats, as well as in forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor responses and no significant detectable toxicity.
Interventions
- BIOLOGICAL Cancer Macrobead placement in abdominal cavity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-01 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283075
The ClinicalTrials.gov registry entry for NCT00283075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cancer Macrobead placement in abdominal cavity is the first listed.
NCT00283075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283075 about?
NCT00283075 is a clinical study titled "Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer". This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tes...
What is the current status of trial NCT00283075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2005-01. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00283075?
The interventions under investigation include: Cancer Macrobead placement in abdominal cavity (BIOLOGICAL).
Who is sponsoring clinical trial NCT00283075?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.